Recent News

• 03.19.2026 - Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
• 03.19.2026 - Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
• 03.12.2026 - Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
• 03.09.2026 - Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
• 03.09.2026 - Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
• 03.09.2026 - Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
• 03.09.2026 - Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
• 03.09.2026 - Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
• 01.12.2026 - Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Recent Filings

• 03.09.2026 - 8-K Current report
• 03.09.2026 - EX-99.1 EX-99.1
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.12.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.06.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.30.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.16.2025 - 4 Statement of changes in beneficial ownership of securities